Smyth, Mark J.

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,474

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine

Inflammasome and immune disordersImmunotherapy and Immune Responses

Cited by 1,898

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,471

Type I interferons in anticancer immunity

Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,305

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 1,294

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,042

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 944

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 894

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 890

Consensus guidelines for the detection of immunogenic cell death

Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology

Immunotherapy and Immune ResponsesCell death mechanisms and regulation

Cited by 832

Perforin-mediated target-cell death and immune homeostasis

Voskoboinik, I., Smyth, M. J., & Trapani, J. A. (2006) · Nature reviews. Immunology

Immune Cell Function and InteractionCell death mechanisms and regulation

Cited by 592

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers

Cited by 496

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine

interferon and immune responsesMechanisms of cancer metastasis

Cited by 487

An Immunosurveillance Mechanism Controls Cancer Cell Ploidy

Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 436

The pre-metastatic niche: finding common ground

Sceneay, J., Smyth, M. J., & Möller, A. (2013) · Cancer and Metastasis Reviews

Cancer Cells and MetastasisImmune cells in cancer

Cited by 422

Membrane-bound Fas ligand only is essential for Fas-induced apoptosis

O’ Reilly, L. A., Tai, L., Lee, L., Kruse, E. A., Grabow, S., Fairlie, W. D., Haynes, N. M., Tarlinton, D. M., Zhang, J.-G., Belz, G. T., et al. (2009) · Nature

Cell death mechanisms and regulationT-cell and B-cell Immunology

Cited by 400

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., et al. (2012) · Journal of Experimental Medicine

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 348

From mice to humans: developments in cancer immunoediting

Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 337

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 300

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 237

Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy

Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research

Immune Cell Function and InteractionCancer Immunotherapy and Biomarkers

Cited by 223

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences

Liver Diseases and ImmunityCell death mechanisms and regulation

Cited by 148

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research

Histone Deacetylase Inhibitors ResearchImmunotherapy and Immune Responses

Cited by 137

CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells

Kara, E. E., McKenzie, D. R., Bastow, C. R., Gregor, C. E., Fenix, K. A., Ogunniyi, A. D., Paton, J. C., Mack, M., Pombal, D. R., Seillet, C., et al. (2015) · Nature Communications

Psoriasis: Treatment and PathogenesisT-cell and B-cell Immunology

Cited by 136